Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $92.49, for a total transaction of $739,920.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at $19,024,730.55. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jim Wassil also recently made the following trade(s):

• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.80, for a total transaction of $854,400.00.

Vaxcyte Price Performance

NASDAQ PCVX traded down $1.23 on Tuesday, hitting $90.37. 869,477 shares of the company were exchanged, compared to its average volume of 906,759. Vaxcyte, Inc. has a twelve month low of $52.74 and a twelve month high of $121.06. The firm has a market capitalization of $11.26 billion, a P/E ratio of -19.65 and a beta of 0.94. The company’s 50 day moving average price is $104.69 and its 200-day moving average price is $90.71.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) earnings per share. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Analyst Upgrades and Downgrades

PCVX has been the topic of several analyst reports. Bank of America raised their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Mizuho raised their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. BTIG Research boosted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and a consensus target price of $147.50.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its holdings in Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after buying an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Vaxcyte by 47.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after buying an additional 419,600 shares during the period. Point72 Asset Management L.P. acquired a new position in Vaxcyte in the 3rd quarter valued at $41,114,000. Finally, Maverick Capital Ltd. raised its holdings in Vaxcyte by 93.7% in the 2nd quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock worth $51,944,000 after acquiring an additional 332,777 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.